AstraZeneca partners with insitro on AI — driven drug discovery for MASH, cardiomyopathies

AstraZeneca entered a drug discovery collaboration and licensing agreement with insitro to develop AI-driven treatments for MASH and cardiomyopathies. Insitro will receive $40 million upfront, with eligibility for up to approximately $1.46 billion in development and commercial milestones. Potential single-digit royalties apply to global commercial sales. * The drugmaker will hold exclusive worldwide rights to advance selected programs identified through the collaboration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202610150600BITN____UKPR__SV_20261015-BIT-3945-0) on October 15, 2026, and is solely responsible for the information contained therein. (C)